Systemic and immune manifestations in myelodysplasia: A multicenter retrospective study

• Published in: Arthritis care & research (2010) Vol. 63; no. 8; pp. 1188 - 1194
• Main Authors: de Hollanda, A., Beucher, A., Henrion, D., Ghali, A., Lavigne, C., Lévesque, H., Hamidou, M., Subra, J. F., Ifrah, N., Belizna, C.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.08.2011
• Subjects: Aged; Aged, 80 and over; Arthralgia - complications; Arthralgia - immunology; Arthritis - complications; Arthritis - immunology; Cryoglobulins - immunology; Female; Fever - complications; Fever - immunology; Humans; Longitudinal Studies; Male; Middle Aged; Myelodysplastic Syndromes - complications; Myelodysplastic Syndromes - immunology; Retrospective Studies; Systemic Vasculitis - complications; Systemic Vasculitis - immunology
• ISSN: 2151-464X; 2151-4658
• DOI: 10.1002/acr.20504

Objective The presence of systemic and/or immune manifestations in myelodysplasia has been currently reported. The influence of these manifestations on the natural outcome of myelodysplastic syndrome has to be considered. We present a multicenter retrospective study (2002–2009) of patients with myelodysplastic syndrome disclosing systemic and/or immune manifestations. Methods Forty‐six patients with myelodysplasia presenting with systemic and/or immune manifestations were compared in terms of survival with 189 patients with myelodysplasia lacking these features. Results The clinical picture in these cases consisted of fever (13%), arthralgia or arthritis (13%), and cutaneous manifestations (67%). Four cases of systemic vasculitis have been reported in our series, and they have a worse prognosis. Immune anomalies were recorded in 29% of the cases, and the presence of cryoglobulins was also associated with a worse prognosis. Conclusion A difference in survival between patients with myelodysplastic syndrome with systemic manifestations and patients lacking these manifestations has been observed in the presence of systemic vasculitis and/or cryoglobulins.